Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.31 |
| ▸ | GAPDH | P04406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444139 | 0.82 | ADORA1 (0.43) | PRMT6P2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL20353076 | 0.77 | P2RY12 (0.45) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL19146392 | 0.77 | P2RY12 (0.42) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL22858497 | 0.77 | P2RY12 (0.35) | P2RY12ADORA1P2RY1 | |
| SCHEMBL20026293 | 0.76 | P2RY12 (0.43) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL19145868 | 0.76 | P2RY12 (0.40) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL24444138 | 0.75 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL19146722 | 0.75 | P2RY12 (0.42) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL21376284 | 0.73 | P2RY12 (0.40) | PRMT6P2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL25293 | 0.73 | P2RY12 (0.48) | P2RY12P2RY2P2RY1P2RY6DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | PRMT6 1514/4885P2RY12 1690/4885PRKAB2 875/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | PRMT6 1514/4885P2RY12 1690/4885PRKAB2 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.